je.st
news
FTC sues AbbVie, Teva over testosterone replacement therapy deal
2014-09-09 11:55:23| Biotech - Topix.net
The Federal Trade Commission filed a complaint Monday against AbbVie and Teva Pharmaceutical Industries alleging the companies illegally blocked American consumers' access to lower-cost versions of the testosterone replacement therapy AndroGel. According to the FTC complaint, AbbVie of Chicago and its partner Besins Healthcare Inc. allegedly filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of AndroGel, which generates more than $1 billion a year in annual sales.
Tags: deal
therapy
replacement
sues
Category:Biotechnology and Pharmaceuticals